Glia in pathological pain: A role for fractalkine
- 31 July 2008
- journal article
- review article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 198 (1-2) , 113-120
- https://doi.org/10.1016/j.jneuroim.2008.04.011
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Immunological priming potentiates non-viral anti-inflammatory gene therapy treatment of neuropathic painGene Therapy, 2009
- CNS‐infiltrating CD4+ T lymphocytes contribute to murine spinal nerve transection‐induced neuropathic painEuropean Journal of Immunology, 2008
- Inhibition of spinal microglial cathepsin S for the reversal of neuropathic painProceedings of the National Academy of Sciences, 2007
- Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in ratsBrain, Behavior, and Immunity, 2006
- Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkineBrain, Behavior, and Immunity, 2006
- Intrathecal polymer-based interleukin-10 gene delivery for neuropathic painNeuron Glia Biology, 2006
- Fractalkine and minocycline alter neuronal activity in the spinal cord dorsal hornFEBS Letters, 2006
- Adenovirus-mediated interleukin-2 gene therapy of nociceptionGene Therapy, 2003
- Staining of glial fibrillary acidic protein (GFAP) in lumbar spinal cord increases following a sciatic nerve constriction injuryPublished by Elsevier ,2003
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000